tisagenlecleucel,axicabtagene ciloleucel
daiichi sankyo,gilead,novartis
[' ipi ', 'cll', 'axi-cel', 'tisa-cel']
congress | #ash22
veit buecklein, discussed outcome differences after car-t in us vs eu pts. eu pts generally had worse survival outcomes. time to transfusion was a mean of 66 days in eu vs 50 days in us. there were no sig differences in toxicity between cohorts. 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm